Table 1 Baseline Characteristics.

From: Establishing measurable residual disease trajectories for patients on treatment for newly diagnosed multiple myeloma as benchmark for deployment of T-cell redirection therapy

 

Triplet Induction

Quadruplet Induction

All Patients

Characteristic

N = 51

N = 279

N = 330

Sex

 Male

32 (63%)

153 (55%)

185 (56%)

 Female

19 (37%)

126 (45%)

145 (44%)

Age

 Median (range)

63 (30-79)

62 (33-79)

62 (30-79)

 Age ≥ 70

16 (31%)

61 (18%)

77 (23%)

Race/ethnicity

 Whites

28 (55%)

187 (67%)

215 (65%)

 Racial/ethnic minorities

20 (39%)

88 (32%)

108 (33%)

Cytogenetic abnormality

 Gain/amplification 1q

10 (21%)

40 (15%)

97 (31%)

 t(4;14)

4 (8%)

35 (13%)

39 (12%)

 t(14;16)

1 (2%)

12 (4%)

13 (4%)

 del(17p)

3 (6%)

45 (17%)

48 (15%)

Cytogenetic Risk Group

 Standard Risk (0 HRCA)

35 (73%)

133 (49%)

167 (53%)

 High Risk (1 HRCA)

9 (19%)

97 (36%)

106 (33%)

 Ultra-High Risk (2 + HRCA)

4 (8%)

40 (15%)

44 (14%)

ISS

 1

21 (55%)

102 (42%)

123 (44%)

 2

13 (34%)

88 (36%)

101 (36%)

 3

4 (11%)

54 (22%)

58 (20%)

R-ISS

 1

17 (49%)

68 (29%)

85 (3!%)

 2

16 (45%)

133 (57%)

149 (51%)

 3

2 (6%)

32 (14%)

34 (13%)

  1. HRCA high-risk cytogenetic abnormality, ISS international staging system, R-ISS revised international staging system.
Back to article page